Keros Therapeutics, Inc. KROS
11.62
0.07
0.61%
as of 25 Sep
- Market cap
- $229.0M
- P/E
- 0.0×
Follow KROS
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
10.95 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | — |
P/S ratio |
3.11 | 166.94 | 62.72 | — | 54.39 | — | 4.99 | 4.99 | — |
P/FCF ratio |
7.15 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | — |
P/Operating CF |
(27.77) | (12.88) | (49.89) | — | (69.78) | — | (6.14) | (6.14) | — |
P/B ratio |
2.50 | 1.04 | 3.82 | — | 5.61 | — | 0.00 | 0.00 | — |
Price to Tangible BV |
2.50 | 1.04 | 3.82 | — | 5.61 | — | 0.00 | 0.00 | — |
EV/Sales |
1.93 | 9.21 | 46.36 | — | 45.23 | — | (0.46) | (0.46) | — |
EV/EBITDA |
6.81 | 0.00 | 0.00 | — | 0.00 | — | 0.26 | 0.26 | — |
EV/Operating CF |
4.38 | (0.20) | (7.54) | — | (18.27) | — | 0.21 | 0.21 | — |
EV/FCF |
4.44 | (0.20) | (7.39) | — | (17.97) | — | 0.21 | 0.21 | — |
Quick Ratio |
14.36 | 20.50 | 13.59 | 16.91 | 20.94 | 37.04 | 1.77 | 2.03 | — |
Current Ratio |
15.45 | 21.45 | 14.25 | 17.27 | 21.23 | 37.27 | 1.99 | 2.23 | — |
Net Debt/EBITDA |
(4.16) | 2.67 | 1.96 | 2.45 | 4.11 | 5.73 | 0.68 | 0.10 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.35% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3.22) | — |
Asset Turnover |
0.51 | 0.01 | 0.00 | 0.00 | 0.08 | 0.00 | 0.52 | 0.73 | — |
Operating CF/Net income |
1.24 | 0.86 | 0.81 | 0.67 | 1.06 | 0.81 | 1.13 | (3.00) | — |
Capex/Depreciation |
(1.03) | (1.57) | (3.02) | (1.84) | (2.71) | (1.06) | (1.30) | 0.00 | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| 19.90% | (41.46%) | (50.19%) | (40.21%) | (23.27%) | (37.45%) | 106.17% | 17.62% | — | |
| 18.24% | (38.01%) | (45.21%) | (37.25%) | (22.39%) | (32.35%) | (73.69%) | (17.12%) | — | |
ROIC |
268.69% | (1,133.80%) | (9,963.71%) | 0.00% | (268.30%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
29.07% | (33.12%) | (46.78%) | (38.59%) | (24.38%) | (17.36%) | (274.54%) | (15.19%) | — |
Average Days of Receivables |
8.70 | 281.92 | 345.66 | 0.00 | 326.87 | 0.00 | 33.65 | 0.00 | — |
Research and Development Expense of Revenue |
53.12% | 4,890.96% | 89,574.83% | 0.00% | 274.34% | 0.00% | 173.79% | 101.11% | — |
Selling, General and Administrative Expense of Revenue |
19.20% | 1,148.00% | 23,068.87% | 0.00% | 106.12% | 0.00% | 31.84% | 12.76% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
11.76% | 982.31% | 19,048.34% | 0.00% | 58.32% | 0.00% | 0.59% | 0.00% | — |
Graham Net Nets |
0.37 | 0.92 | 0.24 | — | 0.18 | — | 0.98 | 0.98 | — |
Graham Number |
18.46 | 0.00 | 0.00 | — | 0.00 | — | 31.57 | 0.00 | — |
Earnings Yield |
9.14% | (31.65%) | (12.06%) | — | (4.31%) | — | (44.83%) | (44.83%) | — |
Free Cash Flow Yield |
13.98% | (27.47%) | (10.00%) | — | (4.63%) | — | (44.21%) | (44.21%) | — |
Revenue per Share |
6.56 | 0.09 | 0.01 | 0.00 | 0.86 | 0.00 | 4.30 | 0.53 | — |
Operating CF per Share |
2.89 | (4.30) | (4.23) | (2.78) | (2.66) | (2.38) | (6.87) | 0.37 | — |
Capex per Share |
(0.04) | (0.05) | (0.08) | (0.05) | (0.04) | (0.02) | (0.12) | 0.00 | — |
Free Cash Flow per Share |
2.85 | (4.35) | (4.31) | (2.82) | (2.71) | (2.40) | (6.99) | 0.37 | — |
Cash per Share |
7.72 | 14.96 | 11.25 | 11.06 | 9.86 | 17.15 | 3.02 | 1.23 | — |
Shareholders Equity per Share |
8.14 | 15.27 | 11.28 | 10.99 | 10.42 | 16.88 | 0.21 | (0.38) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
8.14 | 15.27 | 11.28 | 10.99 | 10.42 | 16.88 | 0.21 | (0.38) | — |
Free Cash Flow |
105.95 | (162.80) | (126.97) | (71.30) | (63.17) | (37.19) | (16.27) | 7.04 | — |
Working Capital |
295.02 | 561.44 | 322.92 | 269.22 | 239.59 | 260.54 | 4.44 | 14.06 | — |
Capital Expenditures |
(1.55) | (1.93) | (2.46) | (1.24) | (1.02) | (0.29) | (0.27) | (0.22) | — |
Net Current Asset Value |
280.55 | 544.56 | 309.48 | 256.41 | 239.36 | 260.00 | (1.53) | (9.06) | — |
EV/EBIT |
6.96 | 0.00 | 0.00 | — | 0.00 | — | 0.25 | 0.25 | — |
Capex to Sales |
0.01 | 0.54 | 16.32 | 0.00 | 0.05 | 0.00 | 0.03 | 0.00 | — |
Net Profit Margin |
35.65% | (5,277.55%) | (101,319.21%) | 0.00% | (292.26%) | 0.00% | (141.36%) | (23.46%) | — |
Price to Operating Income |
11.22 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.35 | 0.29 | 0.20 | 0.33 | 0.28 | 0.38 | 0.29 | 0.22 | — |
Cash ROIC |
17.48% | (14.59%) | (19.39%) | (12.95%) | (13.42%) | (7.13%) | (222.30%) | 14.44% | — |
Accounts Receivable Turnover |
57.03 | 2.46 | 0.31 | 0.00 | 2.21 | 0.00 | 17.57 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
4.28 | 1.44 | 0.49 | 9.42 | 9.11 | 0.57 | 0.57 | — | — |
Average Payables |
3.28 | 5.03 | 4.39 | 3.49 | 2.90 | 2.12 | 1.29 | 1.29 | — |
Average Assets |
476.95 | 492.96 | 338.40 | 281.02 | 262.35 | 140.20 | 19.18 | 13.71 | — |
Average Common Equity |
437.34 | 451.88 | 304.82 | 260.30 | 252.45 | 121.14 | (13.31) | (13.31) | — |
Columns are period end dates